| P/E (FY) | — | Sales (TTM) | $41.1M |
| Earnings (TTM) | -$19.1M | ROE | −93.99% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $146.7M | Trading Days | 1953 |
| 52W High | 3.54 |
| 52W Low | 0.37 |
| % Off High | −34.46% |
| YTD | 49.68% | 1Y | 415.56% |
| 3Y | 213.51% | 5Y | −57.74% |
| Since incept. (ann.) | −20.60% |
| Ann. Volatility (1Y) | 164.69% | Ann. Volatility (3Y) | 132.78% |
| Sharpe (1Y) | 1.69 | Sharpe (3Y) | 0.88 |
| Max Drawdown (1Y) | −57.79% | Max Drawdown (3Y) | −90.33% |
| Beta (3Y, vs SPY) | 2.98 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| MSLE | Satellos Bioscience Inc. | $146.2M | — |
| CNTN | Canton Strategic Holdings, Inc. | $142.4M | — |
| KRRO | Korro Bio, Inc. | $151.4M | — |
| ADCT | ADC Therapeutics SA | $141.2M | — |
| AARD | Aardvark Therapeutics, Inc. | $140.1M | — |
| DERM | Journey Medical Corp | $154.6M | — |
| TNXP | Tonix Pharmaceuticals Holding Corp. | $158.5M | — |
| HURA | TuHURA Biosciences, Inc./NV | $135.6M | — |
| NKTX | Nkarta, Inc. | $158.8M | — |
| OKUR | OnKure Therapeutics, Inc. | $159.6M | — |
| KPTI | Karyopharm Therapeutics Inc. |
| $160.7M |
| — |
| MIST | Milestone Pharmaceuticals Inc. | $133.2M | — |
